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Background. Surgery has previously been the only treatment for lymphatic malformations (LMs), but in the 
head and neck region is challenging due to the risk of scarring, nerve damage, recurrence. Sclerotherapy may 
be a perfect alternative.
Objective. The aim of the study is to determine the efficacy and safety of the OK-432 sclerotherapy in the 
children with craniofacial LMs.
Methods. 81 children with head and neck LM between December 2010 and March 2017were involved into 
the study. The follow-up period was from 6 to 79 months. According to the size of cysts, LMs were classified into 
macrocystic, microcystic, and mixed. The result of the treatment of LMs was determined by the percentage of 
reduction in size as excellent (decrease by more than 90%), good (by 50%–89%), satisfactory (by 20%–49%) and 
none (by less than 20%).
Results. The macrocystic LMs diagnosed in 41.97% of patients, microcystic – in 12.35%, and mixed – in 
45.68% of children. OK-432 sclerotherapy only was performed for 83.9% of patients and in 12.3% in combination 
with surgery. The range of sclerotherapy sessions was from 1 to 11. An excellent result in 96.97% of cases was 
evidenced in the patients with macrocystic LM. Poor result was proved in the patients with microcystic LMs; the 
most of them (55.56%) had satisfactory result. In the patients with mixed LM, an excellent and good result was 
evidenced in 83.33%. After 198 sessions of OK-432 sclerotherapy, complications associated with the treatment 
occurred in 5 (2.52%) cases.
Conclusions. OK-432 sclerotherapy is a safe and effective treatment of head and neck LMs in children. 
Macrocystic LMs proved the best response to OK-432 treatment.
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Introduction
Cystic lymphatic malformations are benign 
vascular lesions, which develop as the result of 
embryological disturbances of lymphatic 
system. Unfortunately, the terms often used to 
describe LMs are imprecise. ‘Cystic hygroma’ 
and ‘lymphangioma’ are often used incorrectly 
to describe malformations. Both of these terms 
should be abandoned, as the suffix -oma con-
notes a neoplasm [1]. In 1982, a landmark 
article by Mulliken and Glowacki suggested a 
classification system designating vascular ano­
malies as either tumours or malformations 
accor ding to their biologic and pathologic 
features [2]. This system was adopted by the 
international society for the study of vascular 
anomalies (ISSVA) and was last updated in 2014 
[3]. Vascular malformations are classified as 
capillary, venous, lymphatic, arterial, and mixed 
lesions, depending on their vascular tissue of 
origin. These lesions are present at birth and 
have a progressive clinical course. The incidence 
of LMs is evidenced in about 1 to 6000 to 1 to 
16,000 live births, with a frequency of hospita-
lization – 3 cases per 100,000 [4, 5]. LMs near 
the principal lymphatic chains in the neck re-
gion are formed when a primordial lymph sac 
loses or fails to re-establish communication 
with the central veins (jugular and subclavian) 
from which it arises [1]. For many years, surgery 
has been the only treatment for LMs of any 
anatomical localization. However, the results of 
the operation were often disappointing, espe-
cially in cases of LM of cheek, tongue, oral 
cavity, neck lateral triangle. The surgical treat-
ment of LM in the region of head and neck is 
accompanied by complications in 12–33% and 
recurrences in 15–53% of cases. In addition, 
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re section of LM does not inhibit bones overg-
rowth in the region of LMs [6, 7, 8]. Recurrence 
and complications are usually the result of 
incomplete preoperative examination and in-
correctly planned treatment. Incomplete resec-
tion provokes rapid growth of malformation, 
causes postoperative lymphorrhea, and re-
current infections [9]. The role of surgical treat-
ment in order to achieve an excellent cosmetic 
result in patients with LMs is questionable. 
When planning an intervention, it is necessary 
to clearly understand that LM can sprout fascia, 
infiltrate different tissues and change normal 
anatomy. The damage of important nervous 
and vascular structures is unacceptable in the 
treatment of benign pathology [10]. LMs usually 
infiltrate skin and subcutaneous tissue [1], 
therefore after the operation the asymmetry 
progresses, and later lymph nodes can sprout 
post-operative scars.
Currently, there is no sufficient evidence in 
the literature to create treatment algorithms 
and help determine the best choice of initial 
therapy, and in recent decades sclerotherapy 
has become the most common treatment op-
tion [5, 11, 12].
According to the results of the literature 
analysis in the PubMed, Medline, Cochrane 
databases, three therapeutic agents are widely 
used for cystic LM local treatment: bleomycin, 
doxycycline and OK-432 (Picibanil) [13]. The 
features of endothelial cells lining the LMs cysts 
determine the effectiveness of the OK-432 for 
the treatment of LM. The mechanism of action 
of the drug is based on the induction of inflam­
mation with subsequent activation of cytokines 
and apoptosis of cells that form the inner layer 
of the cysts [14]. In the cyst fluid the level of 
inflammatory mediators increases that confirms 
the inflammation in response to the injection 
of the drug [15]. The effectiveness of the OK-432 
sclerotherapy in the treatment of cystic LMs has 
been described in small series of some medical 
centres [16, 17]. Since 2011 OK-432 is successfully 
used in Ukraine [18].
Objective of the study is to analyse the 
treatment experience of 81 child patients with 
lymphatic malformations (LM) in the head and 
neck region, and to determine the efficacy and 
safety of the OK-432 sclerotherapy in this cohort 
of patients.
Methods
During the period from December 2010 to 
March 2017, 126 patients with isolated LMs or 
LMs in combination with other congenital 
vascular malformations were treated in the 
OKHMATDYT National Specialized Children 
Hospital. The study includes 81 clinical cases of 
LMs that are localized in the head and neck 
region, representing 64.29% of all patients with 
LMs during the established period of time. The 
follow up period was from 6 to 79 months. 
There were 44 (53.7%) male and 37 (45.1%) 
female patients.
The following visualization methods were 
used to confirm the diagnosis of cystic LMs: 
ultrasound scan in grey-scale and colour Doppler 
was performed at the primary patient's exa-
mination and in dynamics, MRI was per formed 
before treatment and at the stages of treatment, 
CT in urgent situation. According to the results 
of MRI, the size and structure of LMs and also 
their topographical relationship with neighbou-
ring organs and tissues were deter mined as 
particularly mediastinum with retro pharyngeal 
space involvement associated with LMs to the 
level of the hyoid bone. LMs were classified as 
macrocystic, microcystic, or mixed (macrocystic-
microcystic), which has been proven useful in 
other sclerotherapy studies [19]. The classification 
was determined radio graphically by MRI and 
ultrasound examination according to the cysts 
size: macrocystic (formed by cysts with a volume 
of more than 2 cubic centimetres (cc)), microcystic 
(cysts volume – less than 2 cc), and mixed, in 
which the microcystic component exceeds 50%. 
The size of LMs was determined using the ellipse 
square formula. The size of LMs up to 100 cm2 
was evaluated as small, 100–199 cm2 – middle, 
200–299 cm2 – large and more than 300 cm2 – 
gigantic. The result of the treatment of LM was 
determined by the percentage of reduction in 
the lesion size [3, 10] as excellent (decrease by 
more than 90%), good (50–89%), satisfactory 
(20–49%) and unsatisfactory (less than 20% 
reduction in size).
The statistical analysis was performed using 
IBM SPSS Statistics, version 23. The data is pre-
sented as an average of 95 percent confidence 
interval or standard deviation. The qualitative 
data (age, sex, localization, size, etс.) were 
analysed in a univariate analysis with the Pear-
son’s correlation coefficient χ2 test. The logistic 
regression model was used for variants that 
significantly predict the outcome of the treat­
ment and/or the course of the disease. Statis-
tical significance was defined as p<0.05.
Results
Diagnosis of LMs were established prenatal-
ly in 12 (14.81%) patients, at birth in 43 (53.08%), 
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during the first year of life in 12 children 
(14.81%), at the age of one to three years in 4 
(4, 94%) and in 10 (12.35%) children, the clinical 
signs of the disease were manifested at the age 
above three years. Clinical signs of cystic LM in 
the head and neck region were: the asymmetry 
of face and neck due to mass in all children, 
compression of upper airway requiring tra cheo-
stomy before sclerotherapy (n=4, 3.6%), 
transient stridor during the first year of life (n=8, 
7,1%), macroglossia, disarticulation (n=5, 4,5%), 
disturbance of occlusion (n=6, 5,4%), recurrence 
lymphorrhoea in the children with mucosal and 
skin lesions (n=4, 3.6%), excessive salivation 
(n=3, 2.7%), visual impairment (n=1, 0.9%), lym-
phedema of upper limb (n=1, 0.9%). 68 patients 
were treated primary, 13 children underwent 
surgical interventions previously. There pa ti-
ents were treated conservatively with propra-
nolol within 6–12 months without any clinical 
result. According to the visualization of LMs 
using ultrasound and MRI, the topographic 
features of LM and relationship to adjacent 
organs were established. The lesions were 
localized in suprahyoid region in 37 (45.68%) 
children, and in infrahyoid region – in 44 
(54.32%) cases. Bilateral mass were observed 
in 23 (28.39%) children, in other patients LMs 
were localized on the one side of middle line. 
34 (41.97%) patients had macro cystic LMs, in 
10 (12.35%) children microcytic LMs were diag-
nosed, and in 37 (45.68%) children LMs were 
mixed. The size of LMs ranged from 23 to 
517 сm2, in average 135.87 см2. In 37 (45.68%) 
patients LMs were small; in 29 (35.80%) they 
were middle, in 7 (8.64%) LMs were large and 
in 8 (9.88%) LMs were gigantic. In 22 (2716%) 
children mediastinal involvement was diag-
nosed. In children with head and neck LMs 
sclero therapy, surgical and combined treat-
ments were performed.
Three patients (3.7%) underwent surgical 
resection of LMs for the following reasons: 
recurrent inflammation requiring re­hospita­
lization and antibiotic therapy (n=2), difficulty 
in diagnostic due to sudden onset and atypical 
course of the disease (n=1). Recurrence after 
surgery happened in one case. One patient had 
postoperative complication: transient paresis 
of facial nerve branch.
Giant LMs, which occupy several anatomical 
sites and infiltrate muscles, bones, cellular 
spaces deserved a particular attention. Bilateral 
LMs narrowed airway and tracheostomy was 
evidenced in 5 patients. In this series, decannu-
lation was eventually possible in 4 patients after 
multiple sessions of OK-432 sclerotherapy. One 
patient with bilateral LMs, mediastinum, retro-
pharyngeal space and lung involvement died 
due to septic complications. Combined treat-
ment was performed for 10 (12.3%) children, 
which consisted of the following procedures: 
resection of LM, tracheostomy prior to treat-
ment, injection of OK-432 into residual cyst 
ca vity during and/or after surgery (n=5, 6.17%), 
thoracocentesis, pleural and mediastinal 
drainage in the patient with purulent medi-
astinitis with subsequent sclerotherapy after 
the elimination of complications (n=1), sclero-
therapy and correction of scarring and tissue 
deformities (n=3), resection of tongue in the 
patient with pronounced macroglossia, distur-
bance of occlusion (n=1), resection of orbital 
part of LMs due to visual impairment and sub-
se quent sclerotherapy (n=1). The most patients 
(n=68, 83.90%) underwent the OK-432 sclero-
therapy as a single method of head and neck 
LMs. Patients received from 1 to 11 sessions of 
sclerotherapy, in average 2.44±2.21 sessions 
per patient. After 1 session of the OK-432 scle-
rotherapy, an excellent result was achieved in 
24 (29.63%) patients, according to localization 
and structure, these were unilateral macro 
cystic LMs of neck. Involvement of the media-
stinum and retropharyngeal space was not a 
contraindication to the sclerotherapy of LMs. 
In  18  chi ldren with  mediast inal  and 
retropharyngeal part of LMs an excellent result 
was evidenced in 5 (27.78%), good in 9 (50.0%), 
and satisfactory in 2 (11.11%) cases. However, 
in 1 case, the result was poor and in 1 case the 
result of the treatment was unsatisfactory.
After 198 sessions of the OK-432 sclero-
therapy, complications associated with the 
treatment occurred in 5 (2.52%) cases: signi­
ficant oedema with the need for hospitalization, 
puncture, and decompression of the cyst (n=4; 
2.02%), and skin allergic reaction (n=1; 0.51%). 
Response data for macro cystic LMs were 
higher than in other types of LMs with an excel-
lent result in 96.97% and good result in 3.03% 
of patients. In the patients with microcystic LMs, 
no positive result was evidenced, 33.33% of 
cases had a good treatment result, 55.56% were 
satisfactory and 11.11% had no results. In the 
patients with mixed LM, an excellent result was 
evidenced in 33.33% of cases, 50.0% of patients 
had good response to treatment, 11.11% – a 
satis factory one, and 2.77% of patients had no 
result.
Primary efficacy endpoints were evaluated 
using Fisher’s exact test. Covariates used in a 
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univariate analysis included: LM type (macro­
cystic, microcystic, mixed), laterality (unilateral 
versus bilateral), mediastinal and retropha-
ryngeal involvement, prior treatment, age du-
ring the first treatment, gender. It was establi­
shed, that the result of treatment was deter-
mined primarily by the type of LM and previous 
intervention: the best results were evidenced 
in the patients with macrocystic LMs (p<0.005), 
previous intervention reduced the treatment 
efficacy (p<0.005). Covariates that proved a 
significant association with the treatment result 
were used for logistic regression analysis, the 
probability of an excellent and good outcome 
for the patients with macrocystic LM in cases 
of no prior treatment was 86.6%.
Discussion
This article presents a relatively large expe-
rience of the treatment of cystic LMs in the head 
and neck region for a relatively short period of 
time (5.5 years). A peculiarity of this study is 
that for the first time in Ukraine a new approach 
to the treatment of LMs of challenging locali-
zation in children is presented. Treatment of 
head and neck LMs is accompanied by significant 
risks, therefore for children it is necessary to 
choose the most effective and safe way, until 
stronger evidence is present, the difference in 
complication rates is potentially the deciding 
factor in the choice the treatment options [13].
For decades, resection has been the main-
stay for management of LMs. More recently, 
sclerotherapy has become the first­line treat­
ment for head and neck lesions. Experienced 
surgeons welcome the ascendancy of sclerosant 
management. Although some LMs can be 
successfully resected, complications are ex-
pected and results are often disappointing.
One of the most safe and effective ways of 
cystic LMs treatment in children is the OK-432 
sclerotherapy [5, 16]. The OK-432 (Chugai Phar-
maceuticals, Tokyo, Japan) is a lyophilized 
powder of Streptococcus pyogenes (group A, 
type 3, Su strain) incubated with benzylpenicillin. 
The drug was developed in Japan in the late 
1960s as an antitumor agent. Although therapy 
of OK-432 did not increase the survival of the 
patients with cancer, its efficacy was proved in 
pleurodesis in cases of malignant pleural 
involvement. According to these studies, in the 
late 1980s, Japanese authors [17] published the 
first results of using OK-432 as a safe and 
effective treatment for cystic LMs; in 1994, the 
authors published the results of treatment of 
94 patients with LMs [19]. Since then, the 
method has become widely used far beyond 
the borders of the country [20, 21]. The OK-432 
is not exactly a sclerosing agent, because it 
doesn’t destroy vascular endothelium. The OK­
432 induces apoptosis of lymphatic endothelium 
and local cellular inflammatory reaction [7, 16]. 
Recent studies have proved that the pathway 
of the OK-432 action within lymphangiomas is 
probably cellular and cytokine-mediated [7, 16].
Complications due to OK-432 management 
are temporary and predictable [22]. According 
to the results of the literature analysis, no sys-
temic hematological, renal, hepatic or cardiac 
side effects were detected [23], which was 
confirmed in our study. The typical side effect 
of OK­432 sclerotherapy is an inflammatory 
response that is accompanied by local oedema 
and may be potentially dangerous in cases of 
an airway compromised by cervical LMs. In our 
series, in the patients with impaired mechanics 
of breathing, tracheostomy was performed 
prior to treatment. All of those children had 
signs of respiratory failure, tracheostomy as a 
preventive procedure was not performed.
Unfortunately, none of the suggested 
methods for cystic LM treatment in children 
guarantees the complete recovery for all 
patients [24]; however, the introduction of a 
minimally invasive treatment of LM significantly 
reduced the percentage of open surgical inter-
ventions and made it possible to differentiate 
treatment in each individual clinical case.
Conclusions
The OK-432 sclerotherapy is safe and 
effective treatment option of head and neck 
LMs in children. Macrocystic LMs prove the best 
response to the OK-432 treatment, previous 
intervention and increasing the part of micro-
cystic component reduces the efficacy of treat­
ment. Complications associated with the OK-
432 treatment occurred in 2.52% cases.
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